Compare PXED & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | STTK |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.1M | 792.9M |
| IPO Year | 2025 | 2020 |
| Metric | PXED | STTK |
|---|---|---|
| Price | $28.34 | $6.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $44.29 | $10.00 |
| AVG Volume (30 Days) | 71.8K | ★ 773.5K |
| Earning Date | 04-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | N/A |
| P/E Ratio | $17.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.52 | $1.59 |
| 52 Week High | $38.19 | $8.33 |
| Indicator | PXED | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 44.39 |
| Support Level | $29.24 | $5.87 |
| Resistance Level | $31.32 | $7.75 |
| Average True Range (ATR) | 0.88 | 0.34 |
| MACD | 0.33 | -0.12 |
| Stochastic Oscillator | 90.44 | 11.51 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.